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Genetic research is advancing rapidly. One important area for the application of the
results from this work is personalized health. These are treatments and preventive
interventions tailored to the genetic profile of specific groups or individuals. The inclusion
of personalized health in existing health systems is a challenge for policymakers. In this
article, we present the results of a thematic scoping review of the literature dealing with
governance and policy of personalized health. Our analysis points to four governance
challenges that decisionmakers face against the background of personalized health.
First, researchers have highlighted the need to further extend and harmonize existing
research infrastructures in order to combine different types of genetic data. Second,
decisionmakers face the challenge to create trust in personalized health applications,
such as genetic tests. Third, scholars have pointed to the importance of the regulation
of data production and sharing to avoid discrimination of disadvantaged groups and to
facilitate collaboration. Fourth, researchers have discussed the challenge to integrate
personalized health into regulatory-, financing-, and service provision structures of
existing health systems. Our findings summarize existing research and help to guide
further policymaking and research in the field of personalized health governance.
Keywords: personalized health, research infrastructure, trust, regulation, health system, governance,
policymaking
INTRODUCTION
In the wake of the Human Genome Project and the development of new digital technologies,
a whole range of novel possibilities emerges for public health and health care. In referring to
labels such as personalized health, precision medicine, personalized medicine, stratified health,
or 4P (predictive, preventive, personalized, and participatory) medicine (Chataway et al., 2012;
Flores et al., 2013; Andreu-Perez et al., 2015; Heart et al., 2017), researchers have explored
how technological innovations for preventing and treating diseases can be translated into health
practice (Zeggini et al., 2019). In the following, we refer to the ensemble of these terms as
personalized health (PH).
Against this background, some scholars and practitioners have raised high hopes regarding the
potential of integrating PH in existing health systems (Chambers et al., 2016), whereas others
have cautioned against too high expectations (Joyner and Paneth, 2015; Snyderman et al., 2016).
Regardless of how PH will affect the creation of value in the practice of health care and public
health, translating PH into the governance of health is an important problem and a challenge
for policymakers (Stark et al., 2019) as well as a political problem. It requires regulatory efforts,
such as frameworks protecting patients and citizens against discrimination based on their genetic
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profiles (Green et al., 2015). In addition, there is a demand
for regulation and the creation of incentives for providers and
payers to develop products for medical markets (Phillips et al.,
2014; Kukk et al., 2016). Whilst many publications have pointed
to some political challenges regarding the implementation
of personalized health, a comprehensive summary of the
most important governance issues regarding personalized
health is lacking.
In this article, we contribute to the literature, in mapping
of the research dealing with PH governance in a wider sense.
Governance refers to the process and the results of the
coordination of public and private actors involved in (public)
policymaking (Kickbusch and Gleicher, 2012) at the national
and global level (Frenk and Moon, 2013). We conduct a
scoping review, which focuses on the governance challenges
that policymakers (defined in a wide sense, including various
private, and public stakeholders) face in order to implement a
more personalized approach to health care. Therefore, we map
four related challenges, which policymakers face when putting
research into practice to create economic and social value from
PH (Florin and Escher, 2017).
Our analysis points to four governance challenges that
decisionmakers face against the background of personalized
health. First, researchers have highlighted the need to further
extend and harmonize existing research infrastructures in
order to combine different types of genetic data. Second,
decisionmakers face the challenge to create trust in personalized
health applications, such as genetic tests. Third, scholars have
pointed to the importance of the regulation of data production
and sharing to avoid discrimination of disadvantaged groups
and to facilitate collaboration. Fourth, researchers have discussed
the challenge to integrate personalized health into regulatory-,
financing-, and service provision structures of existing health
systems. Our findings summarize existing research and help
to guide further policymaking and research in the field of
personalized health governance.
REVIEW STRATEGY AND METHOD
We conduct a scoping review of the literature, using the
procedure for this method described in the literature (Arksey
and O’Malley, 2005; Thomas et al., 2017). Such an approach
is suitable as our goal is to broadly map existing research
dealing with governance and public policy of PH, rather than
to analyze more specific research questions. We base our review
on a search in the Web of Science Core Collection database
(cf. webofknowledge.com). We include all years (1900–2019),
all document types (journal articles, books, chapters, conference
proceedings, etc.), as well as all Web of Science categories,
i.e., subject areas. We decided to focus our search on one
comprehensive database to keep our review feasible.
Since our review focuses on (latent) theoretical concepts, i.e.,
governance and public policy, we search the literature in two
iterations (see Figure 1). The first search step combines different
terms related to PH with “governance.” In the second search
step, we replace governance with “policy.” To operationalize PH
in the search, we use the following search terms: “personalized
health,” “personalized health care,” “precision medicine,”
“individualized medicine,” “personalized medicine,” “stratified
medicine,” “genetic medicine,” and “genomic medicine.”
We also include all combinations of alternative spellings
(personalized/personalised, individualized/individualised, health
care/healthcare). The exact search string for the first iteration is
(ALL = “personalized health” OR ALL = “personalised health”
OR ALL = “personalized healthcare” OR ALL = “personalised
healthcare” OR ALL = “personalized health care” OR
ALL = “personalised health care” OR ALL = “precision medicine”
OR ALL = “individualized medicine” OR ALL = “individualised
medicine” OR ALL = “personalized medicine” OR
ALL = “personalised medicine” OR ALL = “stratified medicine”
OR ALL = “genetic medicine” OR ALL = “genomic medicine”)
AND ALL = “governance.” For the second iteration, the chain of
keywords is the same but we replace “governance” with “policy”
at the end of the search string.
We define governance essentially as the process and result
of public and private stakeholder coordination with the goal to
actively solve problems through public policy (Goetz, 2008; Trein
et al., 2019). The term governance does also include stakeholders
beyond elected officials and bureaucrats. Therefore, we focus on
“policy” as an alternative search term for governance, rather than
“legislation” or “law.” This approach ensures that we do not miss
articles that are substantially interesting to us but do not use the
term governance.
To conduct the literature review, we followed a five-step
process (Figure 1). Firstly, we carried out the search in the Web of
Science database using the above-mentioned keywords. Secondly,
we read the title and abstract of the publications to verify if
they are interesting for our topic and excluded those that do
not fit. Thirdly, we scanned the full-text of the publications and
retained those that corresponded to the criteria we are interested
in. Fourth, we pursued a for-ward tracking search of the articles,
i.e., we skimmed the titles of the publications that cite the selected
works in Google Scholar (cf. scholar.google.com). Finally, we
embarked in backward tracking, which entailed scanning the
bibliography of the selected publications.
Our search results in two corpora of publications (Figure 1).
The main corpus contains those publications that have emerged
from the selection procedure of the first iteration (focusing on
governance). The publications resulting from the second iteration
(policy) form the corpus of supplementary publications. The
sizes of both corpora differ, which is due to the two different
populations from which we started our search but also as authors
use the term policy much more frequently than governance. The
publications that we retained for the main corpus are journal
articles, one book and one book chapter. The supplementary
material corpus contains mostly articles as well as four books and
two book chapters.
The scanning of titles, abstracts, full-texts, backward and
forward tracking, as well as the subsequent reading applied two
themes covering governance of PH as inclusion and exclusion
criteria for the review process. We developed these themes
based on the literatures related to governance (Ansell and
Torfing, 2016), public policy (Knoepfel et al., 2011), health policy
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FIGURE 1 | Review protocol.
(Papanicolas et al., 2013; Robert et al., 2017; Reibling et al., 2019),
and health governance research (Böhm et al., 2013). Specifically,
the papers that corresponded to the following criteria were
included and retained in the corpus throughout the different
search iterations:
1. Regulations, e.g., laws, guidelines and voluntary codes,
regarding PH and individualized medicine provision,
for example regarding quality standards for precision
medicine. This includes but is not restricted to
regulations of financing and providing preventative
and curative interventions as well as on research and
data-related infrastructure.
2. Public and private actors involved in (public) policymaking
regarding PH and individualized medicine, such as
administrations, governments, health insurers, doctors,
pharmaceutical agencies, patient organizations, and
the relations between them, as well as conflicts and
coordination between these actors.
The first author conducted most of the scoping review and
selected the papers. The second author re-selected some of
the papers as a validity test. The substantial analysis of the
publications’ content uses thematic analysis, which is appropriate
for the procedure of a scoping review (Thomas et al., 2017).
For each of the 47 publication in the main corpus, we record
the region that the paper covers, the methodology the authors
use, the key contents and main results, as well as to which
of the main challenges for the governance of PH the paper
relates to (cf. the synopsis of the reviewed papers provided
in the appendix). In addition, we use the publications from
the supplementary corpus of papers (98) to complement the
discussion of the findings. The supplementary corpus of papers
were selected according to the logic as the main corpus but
they were not thematically analyzed according to the themes
generated through the inductive analysis of the first corpus.
We use the second corpus as a robustness check by picking
articles for additional examples to the narrative presented in
the review. As we manage to identify papers in the control
group that corresponded to the themes in the main corpus,
we conclude that the governance challenges we identify in
the following are valid and can be measured in another
selection of papers.
FOUR CHALLENGES FOR PH
GOVERNANCE
To present the results from our literature review, we start
with a descriptive overview of the publications, focusing at the
overall results from our Web of Science search (left graph,
Figure 2) as well as the specific findings from the thematic
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FIGURE 2 | Development of publications over time.
analysis of the main corpus (right graph, Figure 2). In order
to illustrate the overall search results, we comprised three
groups of search terms that we used for the review. The first
group is entitled genetic medicine and comprises of “genetic
medicine” or “genomic medicine.” The second group is named
personalized health and contains the terms “personalized health,”
“personalised health,” “personalized healthcare,” “personalised
healthcare,” “personalized health care,” or “personalised health
care.” The third group focuses on precision medicine and contains
publications labeled with “precision medicine,” “individualized
medicine,” “individualised medicine,” “personalized medicine,”
“personalised medicine,” or “stratified medicine.” The right graph
in Figure 1 shows how each of these group of publications
appears in combination with the search terms “governance” and
“policy.”
The results show that with respect to governance and policy
the most frequent term authors refer to are related to personalized
medicine, whereas the labels genetic medicine and personalized
health are much less frequent. The use of the label personalized
health is least frequent and increased during the last years (left
Graph, Figure 2). The figure shows how frequently these labels
appear in the Web of Science search in combination with the
terms governance and policy. We re-ran the Web of Science
search in Spring 2021 to include the entire year 2020.
The thematic analysis of the papers reveals four governance
challenges for PH: (1) research infrastructure and practice (RP),
(2) trust building (TB), (3) regulatory framework (RF), and (4)
inclusion in health system (HS). An overview of the coding
for each article can be found in the appendix to the paper
(Table 1). The first governance challenge (RP) entails to create
research infrastructure and practices that correspond to the new
advances in genetic research but also to the new possibilities
of data sharing and analysis that emerge from digitalization.
The second challenge (RP) deals with the building of trust,
notably among patients but also among citizens in general.
The third governance challenge (RF) concerns regulation, for
example regarding data storage and protection as well as non-
discrimination of individuals based on their genetic profiles.
TABLE 1 | Countries mentioned in author affiliations for different articles (main
corpus).

























Frontiers in Genetics | www.frontiersin.org 4 April 2021 | Volume 12 | Article 650504
fgene-12-650504 April 15, 2021 Time: 19:13 # 5
Trein and Wagner Governing Personalized Health
Finally, the fourth governance challenge (HS) deals with the
inclusion of PH into health systems, for example through
the admission and reimbursement of new medications and
treatments. The frequency of these categories in the main corpus
of selected papers is depicted in the right side of Figure 2.
The graph shows that research infrastructure and health system
integration are discussed more frequently than trust building and
regulation. Furthermore, the topic of health system integration
appeared more often in recent years.
Figure 3 illustrates the four governance challenges. Our
thematic analysis reveals that the four identified challenges
overlap, in terms of how they co-occur in different publications.
The thicker the line between the different challenges, the
more both governance challenges are discussed together within
a publication (cf. Figure 2 based on data in Table 1).
Concerning the links between the different challenges, we find
that authors analyze most frequently the link between the
governance of the research infrastructure and the regulatory
framework. Further, studies examine the relation between
trust building and inclusion in health systems on the one
hand, and between trust building and research governance on
the other. Researchers make only weak connections between
research infrastructure and the inclusion of PH in health
systems as well as between trust building and the regulatory
framework (Figure 3).
The governance challenges relate to the policy problems
that stakeholders (Kuhlmann, 2001; Ansell and Torfing, 2016)
face in all health systems. Concerning PH, the most important
stakeholders are: “promoters,” e.g., researchers, commercial and
non-profit developers, sponsors of research and development,
lobbyists and other advocates, “monitors,” e.g., editorial boards,
regulatory bodies and curriculum committees, “providers,”
e.g., clinicians and hospitals, and “users,” e.g., patient-based
organizations (Juengst et al., 2012). These actors are similar
to stakeholder constellations in other health policy issues
(Lewis, 2006; Robert et al., 2017) and they will contribute
in shaping policy responses to the governance challenges. At
the same time, they will be affected by policies for PH.
In the following sections, we discuss the four governance
challenges in more detail.
Research Infrastructure and Practice
The first governance challenge concerns the establishment and
harmonization of infrastructures and practices that assemble the
necessary information for research on prevention and treatment.
Genetic data stored in biobanks is key to the development of
PH services. Already for some time scholars have demanded to
extend the creation of such infrastructure. A literature review
dealing with the diffusion of biobank initiatives concerning PH
holds: “Biobanking services must improve rapidly to serve the
needs of personalized medicine and biospecimen research should
be encouraged and supported at all levels from project funding to
publication of results” (Hewitt, 2011, p. 112). Therefore, a very
important element is that “formal governance structures are a
common and necessary component of biobanks,” such as a formal
access or oversight (Olson et al., 2014, p. 51) and ethics approvals
are a common element (Zika et al., 2011, p. 100).
The creation of biobanks has advanced all around the world,
in recent years (Kohane, 2011; Olson et al., 2014; Zawati et al.,
2018), which offers new opportunities for scientific collaboration,
such as in the Human Epigenome Consortium (Stunnenberg
et al., 2016; Chiapperino and Panese, 2018). This development
renders the harmonization of research infrastructures to allow
for data exchange an even more important challenge (Stark et al.,
2019). This is all the more important since the use of genomic
data coincides with the new possibilities to analyze big data, for
example algorithms (Vayena et al., 2018; Galetsi et al., 2019).
More specifically, harmonizing data sharing requires the
creation of interfaces between research and health care
applications, notably between different technological systems
operating within and between organizations (Kawamoto et al.,
2009; Heart et al., 2017). Particularly the establishment of
compatible electronic health records (EHR) can create a database
for research, linking genetic profiles and the history of health
problems for patients (Kohane, 2011). EHR can become a “tool
for genetic research, addressing concerns on accessibility, return
FIGURE 3 | Four governance challenges.
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of results and privacy and help in educate patients and healthcare
providers” (Caenazzo et al., 2015, p. 4185). Such an infrastructure
would allow to develop research possibilities even further, for
example, in linking EHR and genetic data with geo-spatial
data could provide new insights into individualized medicine
(Schinasi et al., 2018).
Harmonization of research infrastructure is particularly
difficult to achieve in decentralized contexts, such as in the
United States (Joyner and Paneth, 2015, p. 999), but easier
to achieve if there is a national health system, for example
in the United Kingdom. It is likely to be even more difficult
to facilitate research cooperation between nations, particularly
regarding low- and middle income countries where resources
for research are scarce. Nevertheless, the goal of harmonizing
research infrastructures remains important, as cooperative efforts
can contribute to dealing with important health problems, such as
rare diseases (Boycott et al., 2017).
Building Trust
The second challenge for governing PH is to build trust
amongst citizens and patients against the background of technical
innovations related to PH, especially when it comes to the use
of their genetic and personal data (Platt and Kardia, 2015).
This governance challenge refers to building trust between
patients and practitioners, e.g., doctors and researchers. To build
trust, researchers suggest to “(1) address the role of history
and experience on trust, (2) engage concerns about potential
group harm, (3) address cultural values and communication
barriers, and (4) integrate patient values and expectations into
oversight and governance structures” (Kraft et al., 2018, p. 3).
Furthermore, researchers argue that there needs to be room for
bottom-up developed rules and practices in the governance of
biobanks, which includes citizens and helps to increase trust and
transparency (e.g., Meslin, 2010). Scholars have used the terms
reflexive and anticipatory governance to denote this particular
governance challenge related to PH. Reflexive governance means
that decisionmakers include citizens’ input in rule-making related
to biobanks (e.g., Laurie, 2011). Anticipatory governance refers
to the need to anticipate potential negative consequences of new
technologies, such as loss of data in case of personalized medicine,
when creating governance frameworks (Özdemir et al., 2011).
The literature points out that trust-building and the inclusion
of citizens are important for governing PH to address the
risk of discrimination based on genetic profiles (Feldman,
2012). Research based on interviews with geneticists, clinicians,
computer scientists, ethicists, regulators, policymakers, and
program administrators in the United States (US) involved
in the creation of biobanks suggests that the collection of
genetic data bears the risk that this data will eventually be
used to interpret and frame health disparities by conflating race,
ethnicity, and nationality with biological information (Lee, 2015).
Consequently, scholars call for a solidarity-based approach to
implement PH and medicine, i.e., governance practices need to
ensure that discrimination can be avoided effectively (Prainsack,
2018). Thereby, one opportunity to create solidarity is to
pursue data protection governance through community efforts
(Wang et al., 2017).
Researchers have also pointed out that at the individual level,
trust can be built by relying on health care professionals as
intermediaries. One participant from a focus group research
reported, “I might trust my doctor to use my information more
than some third, fourth, fifth party removed in some library
[biobank, precision medicine research program] somewhere. I
know my doctor [.]” (Persaud and Bonham, 2018, p. 26). This
quote illustrates the importance of the trust relationship between
providers of health care services and patients when it comes
to the sharing of individual health data (Laurie, 2011). Survey
data confirms this insight: patients trust particularly their health
care providers when it comes to sharing their personal data
(Bühler et al., 2019). Against this background, the awareness
and education of health care professionals into fostering patients’
trust into PH is crucial (Caenazzo et al., 2015).
Regulatory Framework(s)
The third PH challenge concerns the establishment of regulatory
frameworks. This governance challenges is related to the first
one, which deals with the investment in the creation and
harmonization of research infrastructures. Regulatory efforts in
PH entail ensuring technical compatibility between different
databases, such as biobanks, to encourage researchers and
providers to collaborate in research for new treatments. In
addition, regulatory efforts can work toward protecting citizens
from discrimination and to ensure equitable access to the
promises of personalized medicine.
Concerning data comparability, an important question for
regulators is how to regulate data sharing between different
stakeholders, notably patients, medical practitioners, hospital
operators, pharma- and clinical researchers, as well as health
insurers. Data sharing in PH does not only concern health
systems within a country (Muddyman et al., 2013; Palanisamy
and Thirunavukarasu, 2017), but also data exchange between
different countries. This problem poses a challenge not only
for high income countries but also for low- and middle
income economies. A review of the biobanks in low- and
middle-income countries demonstrates that there is a lack of
harmonized data sharing systems and that data formatting
is often not standardized (Zawati et al., 2018). Common
regulations and standards can help to solve this problem. This
regulatory dimension has a large transnational component and
requires establishing regulations beyond single countries to
support innovation. For example, pharmacogenomics requires
the creation of a transnational regulatory regime that comprises
a network including regulatory agencies, academic scientists
and industry, and aim at creating a space for data sharing
and to set standards that span across jurisdictional boundaries
(Hogarth, 2012).
Another important theme for regulation of PH is to
ensure genetic non-discrimination of individuals through the
information contained in biobanks or EHR in order to protect
privacy concerns (Williams et al., 2016). This seems somewhat
self-evident and necessary. Nevertheless, researchers have held
that it might be a challenge to implement such regulations
as they could slow down innovation (Juengst et al., 2012).
For example, the United States Congress passed the Genetic
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Information Non-discrimination Act (GINA) in 2008 (Dressler
and Terry, 2009; Feldman, 2012; Feldman and Darnel, 2013;
Green et al., 2015; Rothstein, 2018). The legislation aims
to rule out genetic discrimination regarding health insurance
admission and employment. Feldman (2012), p. 743 states that
“GINA prohibits insurers from using genetic information to
adjust group or individual premiums, deny coverage, or impose
preexisting condition exclusions, and makes it illegal for them
to require or request genetic testing or intentionally obtain
genetic information.” The law received overwhelming support
in the United States Congress and has important implications
for medical providers and health care organizations, which must
familiarize themselves with the specificities of the act. Other
countries, for example European Union (EU) member states,
have also legislated to prevent discrimination on a genetic
basis (Borry et al., 2012). Protection against discrimination
and diffusion of health care innovation is a transnational
regulatory challenge, cf. the jurisdiction of European directives
(Salas-Vega et al., 2015). The EU’s general data protection
regulation and the Organization for Economic Co-operation and
Development’s recommendations for digital health governance
are two cases that exemplify the transnational dimension
(Vayena et al., 2018).
In addition to rulemaking, rule implementation is an
important challenge. In other words, data regulation is more
than passing laws, it also concerns the implementation of such
regulations in practice. For example, scholars have emphasized
the need for data controllers who are able to support researchers
in dealing with legal challenges: “It cannot be the responsibility
of the researcher who wants to access data to handle the
legal intricacies of EU and national data protection legislations;
this must be done by the data provider who acts as a data
controller” (Kuchinke et al., 2016, p. 17). Such practices not
only protect researchers from legal challenges emerging from
research dealing with PH, but they also make the research process
more transparent (Kaye et al., 2018), and therefore increase the
trust in PH and medical innovation. Eventually, the regulatory
architecture for PH needs to include ethics regulation and a
committee for genomic research to ensure “accessibility, return
of results and privacy and help in educate patients and healthcare
providers” (Caenazzo et al., 2015, p. 4185).
Integration Into Health Systems
The fourth governance challenge is to integrate PH (Hedgecoe,
2004; Nwaru et al., 2017; Minari et al., 2018) into existing
health systems, in other words, to integrate PH in the regulation,
financing, and provision of public health and health care (Trein,
2018). In many countries, for example in Japan, Great Britain,
and the United States, policymakers have included precision
medicine schemes in the context of national health systems
(Minari et al., 2018).
But how exactly could PH be integrated into existing health
systems? One proposition in the literature suggests to assess
the inclusion of PH in national health systems along six key
themes: healthcare system, governance, access, awareness,
implementation, and data. Specifically, the governance
dimension, should entail a national strategy, comprehensive
legislation and guidelines, as well as an ethical, social, and legal
framework regarding the provision of personalized medicine and
genetic data. Further indicators are a national research center
or large-scale research initiative, a consumer test legislation or
code of conduct, and working groups with multiple stakeholders
(Chong et al., 2018, p. 2 and Table 2). For example, the
United States created the national Precision Medicine Initiative
(PMI). Its goal is to create more genetic research programs,
which should ideally result in better health care programs
(Sabatello and Appelbaum, 2017). Scholars have linked the PMI
to the idea of a genetic citizenship, which entails the exchange of
personal information in exchange for information from genetic
research to make the best health-related choices for themselves.
Put differently, this concept entails a new contract between
citizens and the state – respectively, health care providers – and
entails risks, benefits, and responsibilities for each participant
(Sabatello and Appelbaum, 2017).
In addition, including PH into existing health systems requires
to fit new services and practices with national regulations and
financing schemes. In the following, we illustrate this problem
based on five examples.
1. Firstly, this entails the implementation of EHR in existing
routines of health care and to include information beyond
the clinical health data (Heart et al., 2017; Lu et al., 2018).
2. Secondly, it requires the assessment and certification
of genetic tests’ actual public health value. Nowadays,
consumers can choose between a widening array of genetic
tests but it is not clear to what extent these tests effectively
contribute to improving individual and public health and
should therefore be reimbursed by health insurance (Hall
et al., 2010; Caulfield and McGuire, 2012).
3. Thirdly, there is the challenge to approve new treatments
(Bertier et al., 2016), for example orphan drugs or
personalized drugs (Garrison et al., 2008) as well as new
cancer therapies, such as precision immunotherapy for
metastatic melanoma (Chin-Yee et al., 2018, p. 383).
4. The fourth element about integration is the reimbursement
of these new treatments and their inclusion in health care
payers’ plans (Meckley and Neumann, 2010; Messner et al.,
2016). New personalized treatments and drugs tend to be
expensive (Degtiar, 2017), which raises the question how
to ensure equity in access (Williams et al., 2016).
5. Fifth, the literature points out that PH will increase
or reduce the disparities between medical health care
and public health. On the one hand, genetic testing
provides new possibilities for preventative medicine, such
as stillbirth prevention (Ker, 2018). On the other, the
predictive power (Bourret et al., 2011; Juengst et al., 2012)
of precision medicine might re-enforce health inequalities
rather than decreasing them (Khoury and Galea, 2016;
Chin-Yee et al., 2018). The last point is particularly relevant
since it is very unlikely that “personalized” medicine with
individually designed plans for prevention and treatments
becoming reality in the near future. The development
of stratified medicine that considers genetic variations
between different groups is more likely. This makes equity
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TABLE 2 | Synopsis of reviewed papers (Main corpus).
Reference Region Methodology Key contents and main results RP TB RF HS
Dry et al. (2017) United States
(California)
Deliberative community
engagement (N = 51)
Biobank governance and oversight recommendations
Educate the public, share samples broadly, monitor researcher behavior




No empirics Commentary Pairing disease biobanks with electronic health records (EHR) for research
Specific ethics committees for each biobank to improve governance
Committees to set up EHR utilization guidelines and to address concerns
X X
Hewitt (2011) No empirics Literature review Description of advances in biobanking and biospecimen research
Quality management and professional organization of biobanks
Improvement of collection models and patient protection
X X
Meslin (2010) United States (Indiana) Case reviews (N = 279
and 1000)
Building trust and transparency in biobanks governance structures
Top-down steering to be complemented with bottom-up governance








Review of challenges and opportunities identified by biobank researchers
Informed consent, access policy, and data sharing is critical











Operational, sustainability, and funding challenges in biobanking
Resources, viability, and usefulness of running biobanks
Technologies and strategies to minimize overly complex structures
X X
Kaye et al. (2018) No empirics Commentary National governance hinders international exchange of research data
Need of public consultations on access and use data-sharing issues
Digital technologies to encourage accessibility, transparency, accountability
X X
Laurie (2011) United Kingdom Conceptual
investigation
Reflexive governance as approach without specific basis in law
High-level policy documents guide decisions and practice
Commitment among participants, researchers and society avoids regulation
X X
Lee (2015) No empirics Ethnographic research Institutional practices of classifying and creating taxonomies
Biobanks as political artifacts framing health differences in populations




No empirics Commentary Systems approach to pharmacovigilance and risk governance
Need for centers for panvigilance and global clinical trials




United States Commentary Term “precision medicine” is overly ambitious
Systems approaches relate to multiple ideas and aims
United States genetic research is no public good due to the private health care
providers
X X
Kohane (2011) No empirics Review article Use of electronic health records and related information for genetic research
Link genetic studies to clinical health care delivery




No empirics Statistics (2007–2014),
case reviews
Development of big data in biomedical and health informatics
Big data will advance disease management (diagnosis, prevention, treatment)




Netherlands Case study Biobanking infrastructures positioned between healthcare and research
Changing relationship between care and research biobank governance






Microbiome research adds to biobanking and data sharing complications
Revisit of privacy, consent, ownership, results, governance, and benefit sharing






Literature review Standardization of data sharing and access in biobanking
Data access governance needs to be flexible and reflexive




No empirics Literature review Support of clinical genetics by carefully designed biobanks
Setting up a biobank and linkage to electronic health records




No empirics Conceptual article Technology foresight analysis defining “environtome” and “social proteome”
Personalized health beyond genomics with big data technologies (proteomics)





No empirics Literature review Success of big data healthcare applications depends on architecture and tools
Diversified data analytical capabilities for handling sources of data needed
Eco systems to include patients, doctors, hospitals, researchers, and insurers
X
(Continued)
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TABLE 2 | Continued
Reference Region Methodology Key contents and main results RP TB RF HS
Ingrams (2019) No empirics Conceptual article Application of Dahl’s theory of democracy to health data governance
Recognition of the role of citizens in policy making







Commentary Ethical dimensions in national strategies for precision medicine
Mitigate undesirable impact on privacy, commercialization and public trust
Approaches to consider equity, social justice, resources and politics
X X X
Dove (2015) No empirics Literature review Review of international disease and database consortia and projects
Coordination is critical in international governance of biobanking




No empirics Commentary Crucial role of health care providers in creating trust of patients
Physicians to serve as agents and mediators in precision medicine programs





United States Commentary Active, informed participation in research through “genomic citizenship”
Analysis of risks and benefits for participating in such initiatives






Case studies Translational biomedical research requires large pools (“citizen science”)
Initiatives to include an analysis of the role of citizenry
Terms “participation,” “involvement,” and “engagement” to be clarified
X X





deliberations (N = 180)
Moral concerns of donors in biobanking
Participants worry about ethical problems of consent
Public trust and (dis)trust in science to be addressed
X
Kraft et al. (2018) United States (Greater
San Francisco Bay
area)
Focus groups (N = 122) Build/maintain long-term, trust beyond consent with patient-participants
Address experience, concerns, cultural values, communication barriers




United States Survey of citizens
(N = 447)
Public trust in health information sharing systems
Primary care provider and psychosocial factors positively influence trust
Privacy concerns and knowledge about sharing are negatively associated
X
Rose (2013) United States Case study Trust in Patient Advocacy Organizations (PAO)
Limited industry funding to promote PAO trustworthiness







interviews (N = 34)
Patients to receive an updated interpretation of their genetic information
System responsibilities come with governance and legal issues
Interplay with professional obligations (duties, responsibilities, obligations)
X X




Impact of pharmacogenetics technology on clinical practice
Industry and researchers have a simplified view compared to clinicians




Germany Case study Stratified prevention as a major change for health policy in Germany
Individual control and understanding of health information required
Updated governance and evidence-based development of taxonomies
X X
Prainsack (2018) No empirics Conceptual article Solidarity concepts to depart from the assumption of rational individuals
Relational understanding of personal and collective preferences




No empirics Legal analysis Development of a legal assessment tool for data access and sharing
Provides assessments and recommendations for researchers
Model develops usage scenarios and requirement clusters for data sharing
X




Pharmacogenomics to transform drug discovery and development
Transnational regulatory regime encompassing national actors needed




United Kingdom Case study Analysis of a data management system implementation (UK10K)
Reconciliation of data-sharing principles and system practicalities






Management of data in biobanks and sharing infrastructures
Practical implementation of the European Data Protection Directive
Governance to consider privacy concerns over individual data
X
Song et al. (2017) No empirics Topic model Patent landscape dominated by therapeutic patents
Focus on areas of oncology and neurodegenerative and infectious diseases




Italy Commentary Integration of genomics into National Health Service
Areas of focus: prevention, diagnosis, and care
Consider effectiveness (evidence-based) and sustainability (cost-effectiveness)
X
(Continued)
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TABLE 2 | Continued
Reference Region Methodology Key contents and main results RP TB RF HS
Bowman et al.
(2016)
United States (Arizona) Commentary Availability of health and blood tests in local pharmacies
Interpretation of health data shifts from professionals to consumers








interviews (N = 11)
Adoption of personalized medicine in Southeast Asia’s health systems
Governance, access, awareness, implementation, and financing are reviewed
Balancing equity among populations and improving efficiency are critical
X
Feldman (2012) United States Commentary Genetic Information Non-discrimination Act in health insurance/employment
Examination of fear and reality of genetic discrimination




No empirics Commentary Ethical, legal and social implications of genetic research on public health
Infectious disease management procedures in health care practice are affected
Balance health-related benefits/harms with impact of policy interventions
X
Gray et al. (2019) No empirics Literature review Precision medicine to add value in lifestyle medicine beyond genomics
Provide suitable types of support to people to adopt a healthy lifestyle




No empirics Conceptual article Anticipatory governance for vaccinomics and post-genomic technologies
Response to impredictability of consequences of a technology in early stages




No empirics Commentary Citizen engagement as prerequisite for policy change in public health
Governance, consent, trust, data-knowledge cycle to be improved






Conceptual article Pricing and reimbursement policies of genomic tests
Strategies to include universal access, cost monitoring and appropriate use
Develop research capacity and invest in human resources
X
RP, Research infrastructure and practice; TB, Trust building; RF, Regulatory framework; HS, Inclusion in health system.
problems all the more relevant (Juengst et al., 2012; Tutton,
2012; Minari et al., 2018).
At an organizational level, these policy challenges need to
be absorbed by the existing structure of the national health
systems. For example, in Italy, “the State-Region conference
approved and published the national plan of public health
genomics. A further step has recently been made with the
approval of a ‘National Plan for Innovation of the Health
System based on omics sciences.”’ This plan includes measures
to introduce the use of big data in the health system, but it
also aims to support economic growth through investment in
PH (Boccia et al., 2017, p. e12782-2). Taking a comparative
perspective, scholars have focused on organizations that are
responsible for managing genetic tests. In the United States,
the Centers for Medicare and Medicaid Services and other
government agencies are responsible for genomic testing and
for creating regulatory standards to integrate genomic testing
in clinical practice. The Secretary’s Advisory Committee on
Genetics, Health and Society and the National Human Genome
Research Institute deal with the question on how genetic tests can
be reimbursed for patients (Vozikis et al., 2016, p. 353). In the
EU, genetic tests are regulated by the EU directive on medical
device regulations which requires certification of the device to
have a “Conformité Européenne” (CE) mark. Reimbursement of
tests is regulated differently in each EU country. For example, “in
Germany, it is administered by Der Gemeinsame Bundesausschuss
(GBA), in France by La Haute Autorité de Santé (HAS), in
the United Kingdom by the National Health Service (NHS),
in Italy by Il Servizio Sanitario Nazionale (SSN), and in Spain
by El Instituto Nacional de la Salud (INS)” (Vozikis et al.,
2016, p. 354).
Up to know, it remains open how different political actors have
taken action to integrate personalized health into the contexts of
different health systems. Nevertheless, a comprehensive analysis
on how PH has been included in health governance is lacking
for European countries. What is more, we know much less
about the role of health system integration of PH in low- and
middle-income countries.
CONCLUSION
This article presents the results of a scoping review of
the literature on PH governance. Our review shows that
policymakers face particularly four governance challenges
when putting PH into practice: (1) creating, maintaining and
harmonizing an infrastructure for research, (2) building and
fostering trust in PH amongst citizens in general and patients
in particular, (3) establishing regulatory frameworks to ensure
cooperation and to avoid discrimination, and (4) integrating PH
into existing health systems.
These four challenges are relevant for practitioners and
researchers alike. Concerning the research agenda that lies
ahead, our review suggests that scholarship dealing with the
implementation of PH should focus on research questions
emerging from the four challenges for governing personalized
health. Scholars aiming at a specific research question could
direct their efforts at the link between trust building and
regulatory frameworks on the one hand, as well as on the
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relationship between the research infrastructures and health
system integration on the other. Both topics are highly important
for realizing PH in practice. Nevertheless, according to our
review, scholars have so far devoted limited attention to
these questions. Furthermore, there is room for a rigorous
empirical comparison that analyzes how governments in different
countries with different health systems have addressed the four
governance challenges outlined above. Specifically, researchers
should explore why there are (potential) differences and
similarities in how governments address the four challenges,
for example in taking into account recent developments in
research on health care systems (e.g., Papanicolas et al., 2013;
Reibling et al., 2019).
The four governance challenges uncovered by this literature
review refer to other topics, which scholars of governance
raised in the literature, such as transparency, accountability,
protection of human rights, international standards, and citizen
participation (Papadopoulos, 2007; Merry, 2011; Ansell and
Torfing, 2016). Our findings show that the demand for
trust building requires a transparent usage of genetic data.
Furthermore, trust building entails that citizens can participate
actively in the research process. We also demonstrate that
creation of a regulatory framework and standards is part of the
literature personalized health governance, which is important
to ensure human rights protection at the national and a global
level. Furthermore, the development of regulations and standards
is relevant to govern risks, determine liability and to protect
individuals from unequal treatment regarding personal health.
Thus, our review paves the way for future research on the
governance of personalized health.
In addition, the four governance challenges are relevant for
practitioners as they give an overview of the most relevant policy
challenges for PH practice. To be clear, the four challenges
that arise from our scoping review are an empirical mapping
of the state of the literature, rather than a normative agenda.
We do not call for a top-down approach to addressing these
challenges by way of central state intervention. According to our
interpretation, it must be the goal of PH policymaking to address
these four challenges in a balanced manner. To achieve this
aim, PH governance requires including a variety of stakeholders
in order to co-produce sustainable governance arrangements,
rather than to govern in a hierarchical fashion from the top.
We are well aware that such demands are ubiquitous and
relevant for many policy problems. Nevertheless, our results
show, however, that this approach is also relevant for the field of
personalized health.
Finally, we would like to point the reader to the limitations
of this review. Firstly, our search is based on one database
(Web of Science). This database has a broad reach and is likely
to pick up published and gray literature. The search retrieved
documents classified as Articles, Editorial Materials, Proceedings
Papers, Letters, Reviews, Book Chapters, Meeting Chapters,
Books, and Book Reviews. Thus published research that is only
indexed in other databases might have been missed. Secondly, our
search did not cover press articles. Future research could reveal
how the scientific debate on personalized health relates to the
debate in newspapers.
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